News Year None2021202020192018 April 27, 2021 Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists March 30, 2021 Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients March 24, 2021 Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update March 15, 2021 Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation March 2, 2021 Equillium to Present at the H.C. Wainwright Global Life Sciences Conference February 18, 2021 Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference February 12, 2021 Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience February 9, 2021 Equillium Announces the Appointment of Katherine Xu to the Board of Directors February 5, 2021 Equillium Announces Closing of $30 Million Registered Direct Offering February 4, 2021 Equillium Announces Pricing of $30 Million Registered Direct Offering Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
April 27, 2021 Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
March 30, 2021 Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
March 24, 2021 Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
March 15, 2021 Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
February 12, 2021 Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
